These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24801755)

  • 1. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer?
    Mirandola L; Nguyen DD; Rahman RL; Grizzi F; Yuefei Y; Figueroa JA; Jenkins MR; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2014 Oct; 33(5):417-27. PubMed ID: 24801755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer.
    Mirandola L; Yu Y; Cannon MJ; Jenkins MR; Rahman RL; Nguyen DD; Grizzi F; Cobos E; Figueroa JA; Chiriva-Internati M
    Gynecol Oncol; 2014 Dec; 135(3):573-9. PubMed ID: 25284038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Galectins in Multiple Myeloma.
    Storti P; Marchica V; Giuliani N
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varied expression and localization of multiple galectins in different cancer cell lines.
    Satelli A; Rao PS; Gupta PK; Lockman PR; Srivenugopal KS; Rao US
    Oncol Rep; 2008 Mar; 19(3):587-94. PubMed ID: 18288388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-9 - ligand axis: an emerging therapeutic target for multiple myeloma.
    Shil RK; Mohammed NBB; Dimitroff CJ
    Front Immunol; 2024; 15():1469794. PubMed ID: 39386209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tandem transplantation with peripheral autologous hematopoietic blood stem cells in treatment of oncologic and hematologic malignancies. Initial results of the Donauspital, Vienna].
    Ruckser R; Kier P; Sebesta C; Kittl E; Kurz M; Selleny S; Höniger S; Scherz M; Habertheuer KH; Zelenka P
    Wien Med Wochenschr; 1995; 145(2-3):41-4, 46-7. PubMed ID: 7762251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectins in hematological malignancies.
    Giordano M; Croci DO; Rabinovich GA
    Curr Opin Hematol; 2013 Jul; 20(4):327-35. PubMed ID: 23695449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.
    Chiriva-Internati M; Cobos E; Kast WM
    Int Rev Immunol; 2007; 26(3-4):197-222. PubMed ID: 17558744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in multiple myeloma: current strategies and future prospects.
    Yi Q
    Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer biology and immunotherapy.
    Latha TS; Panati K; Gowd DS; Reddy MC; Lomada D
    Int Rev Immunol; 2014 Oct; 33(5):428-40. PubMed ID: 24911597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human galectins induce conversion of dermal fibroblasts into myofibroblasts and production of extracellular matrix: potential application in tissue engineering and wound repair.
    Dvořánková B; Szabo P; Lacina L; Gal P; Uhrova J; Zima T; Kaltner H; André S; Gabius HJ; Sykova E; Smetana K
    Cells Tissues Organs; 2011; 194(6):469-80. PubMed ID: 21494018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for ovarian cancer: recent advances and perspectives.
    Zsiros E; Tanyi J; Balint K; Kandalaft LE
    Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
    van de Donk NW; Kamps S; Mutis T; Lokhorst HM
    Leukemia; 2012 Feb; 26(2):199-213. PubMed ID: 21852787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
    Kobayashi T; Kuroda J; Ashihara E; Oomizu S; Terui Y; Taniyama A; Adachi S; Takagi T; Yamamoto M; Sasaki N; Horiike S; Hatake K; Yamauchi A; Hirashima M; Taniwaki M
    Leukemia; 2010 Apr; 24(4):843-50. PubMed ID: 20200560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-3--a jack-of-all-trades in cancer.
    Newlaczyl AU; Yu LG
    Cancer Lett; 2011 Dec; 313(2):123-8. PubMed ID: 21974805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?
    Chiriva-Internati M; Cobos E; Cannon MJ
    Int Rev Immunol; 2011; 30(2-3):67-70. PubMed ID: 21557634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.
    Chen YX; Wang Y; Fu CC; Diao F; Song LN; Li ZB; Yang R; Lu J
    Endocr Relat Cancer; 2010 Mar; 17(1):39-50. PubMed ID: 19776289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion.
    Zou J; Glinsky VV; Landon LA; Matthews L; Deutscher SL
    Carcinogenesis; 2005 Feb; 26(2):309-18. PubMed ID: 15528216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immunotherapy of multiple myeloma: perspectives and perplexities.
    Di Bernardo A; Macor P; Guarnotta C; Franco G; Florena AM; Tedesco F; Tripodo C
    Expert Opin Biol Ther; 2010 Jun; 10(6):863-73. PubMed ID: 20367529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.